CannaGlobal, Sansero Life Sciences and Rise Wellness To Merge, Creating a New International Psychedelics Company

CannaGlobal, Sansero Life Sciences and Rise Wellness To Merge, Creating a New International Psychedelics Company
CannaGlobal, Sansero Life Sciences and Rise Wellness To Merge, Creating a New International Psychedelics Company

TORONTO--(BUSINESS WIRE)--CannaGlobal, Sansero Life Sciences, and Rise Wellness today announced the creation of CannaGlobal Wellness, a global psychedelics leader focused on psilocybin and other natural compounds to promote emotional, mental, and physical wellness. Leveraging an internationally renowned team with a track record of success, the company will be ideally positioned in the evolving psychedelics industry.


“Three hundred million people worldwide suffer from depression, and one out of 13 people have an anxiety disorder”


Lorne Gertner, co-founder of Tokyo Smoke, Cannasat Therapeutics (now Cynapsus Therapeutics), and PharmaCan Capital (now The Cronos Group), will serve as Chairman. Leveraging his vast experience and extensive network in the global cannabis and wellness industries, he founded CannaGlobal to pursue the advancement of cannabis and global wellbeing. Steve Sadoff, co-founder of Sansero, will serve as CEO. Mr. Sadoff has 15 years of experience developing, launching and growing brands and products within highly regulated environments including nutraceuticals, natural health and cannabis. Irie Selkirk, will continue to lead Rise Wellness, leveraging her extensive experience as a retailer, patient support expert and as an educator, facilitator, and leader in the cannabis and psychedelics industries. Dr. Darryl Hudson, PhD Molecular Biology and Genetics, will take on the role of Chief Science Officer, bringing with him a deep understanding and unparalleled expertise in the areas of plant molecular biology, neuroscience and genetics in cannabis and psychedelics.

“This is a major step forward for mental health in Canada and around the world,” said Gertner. “Psilocybin is proven to have real benefits for treating serious conditions that affect millions of people, and we are excited to be on the cutting edge of helping people improve their lives and making the world a better place, which I am passionate about and have spent the majority of my life pursuing.”

CannaGlobal Wellness will fuse Sansero’s best-in-class science team and capabilities in the development of novel formulations and intellectual property in psilocybin-based treatments, Rise Wellness’ delivery of industry-shaping immersive healing experiences, and CannaGlobal’s worldwide network of natural wellness pioneers. The synergies created by this merger will enable the company to offer an extensive and scalable menu of wellness solutions in the short term, while also accelerating the development and commercialization of psilocybin-based neurotherapeutics.

“Three hundred million people worldwide suffer from depression, and one out of 13 people have an anxiety disorder,” Sadoff said. “Without effective treatment, these illnesses can be debilitating, and even life threatening. But current treatments aren’t universally tolerated and always effective. Our formulations have indicated that psilocybin, when combined with natural molecules and world-class immersive healing environments, offers a superior alternative to single-molecule drugs that merely suppress symptoms. This merger gives us the infrastructure and network to bring new, game-changing, neurotherapies to market with maximum efficiency.”

Stoic Advisory Inc. is acting as Financial Advisor for CannaGlobal and its Board of Directors. Wildeboer Dellelce LLP is acting as legal advisors to CannaGlobal. Borden Ladner Gervais LLP (BLG) is acting as legal advisor to both Sansero and Rise.

Contacts
Corey Herscu for CannaGlobal Wellness.
corey@verbfactory.com
416-300-3030
Read More
Tags
Psychedelic Stocks, Psychedelic Stocks, Psychedelics